Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Background Enfortumab vedotin (EV) is an antibody‐drug conjugate showing significant overall survival (OS) benefit versus chemotherapy for patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC) in EV‐301. This subgroup analysis was conducted to further analyze...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cancer medicine (Malden, MA) Ročník 12; číslo 3; s. 2761 - 2771
Hlavní autori:	Matsubara, Nobuaki, Yonese, Junji, Kojima, Takahiro, Azuma, Haruhito, Matsumoto, Hiroaki, Powles, Thomas, Rosenberg, Jonathan E., Petrylak, Daniel P., Matsangou, Maria, Wu, Chunzhang, Campbell, Mary, Yamashiro, Mayumi
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States John Wiley & Sons, Inc 01.02.2023 John Wiley and Sons Inc Wiley
Predmet:	Antibodies, Monoclonal, Humanized - therapeutic use antibody‐drug conjugate Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bladder cancer Cancer therapies Carcinoma, Transitional Cell - pathology Cell cycle Chemotherapy Diabetes Drug dosages East Asian People enfortumab vedotin FDA approval Humans Japanese Metastases Metastasis metastatic Monoclonal antibodies Paclitaxel Patients Population Population studies Safety Scintigraphy Survival Targeted cancer therapy Urinary Bladder Neoplasms - pathology Urothelial carcinoma United States > US Japan antibody-drug conjugate urothelial carcinoma metastatic Japanese enfortumab vedotin
ISSN:	2045-7634, 2045-7634
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!